Novartis (NVS) has launched a new innovation hub, Novartis Biome sub-Saharan Africa (SSA), to improve healthcare in the region by developing innovative business models and...
According to a German newspaper, Swedish-based investment group EQT and the Struengmann family of Germany are considering a joint move to purchase the Novartis AG's (NYSE: NVS)...
In a bid to take on well-established rivals, Novartis (NVS) is formulating a non-traditional sales strategy to promote the company’s cholesterol-busting therapy...
Los Angeles, USA, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Follicular Lymphoma Clinical Trials | A Drug Pipeline Analysis Report 2021 | DelveInsightThere are approximately 50+ key...
China is not only cracking down on kiddie playtime. It also is absorbing bankruptcy claims from real estate developer Evergrande.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 499.80 | 525.20 | 457.50 | -64.60 | -11.45% | 18.74M | London | |||
| 121.56 | 127.82 | 117.00 | -15.98 | -11.62% | 106.81M | London | |||
| 2,635.00 | 2,711.50 | 2,635.00 | -210.5 | -7.40% | 4.54M | London | |||
| 109.62 | 113.54 | 109.40 | -4.48 | -3.93% | 283.54M | London | |||
| 279.15 | 280.40 | 277.15 | -1.20 | -0.43% | 23.97M | London | |||
| 1,472.50 | 1,495.00 | 1,452.50 | -55.50 | -3.63% | 554.35K | London | |||
| 1,303.50 | 1,354.50 | 1,303.50 | -116.00 | -8.17% | 4.74M | London | |||
| 286.00 | 286.00 | 286.00 | 0.00 | 0.00% | 0.00 | London | |||
| 1,053.50 | 1,077.50 | 1,051.50 | -62.00 | -5.56% | 2.98M | London | |||
| 7,848.00 | 7,976.00 | 7,804.00 | -262.0 | -3.23% | 190.95K | London | |||
| 1,384.50 | 1,414.50 | 1,375.50 | -88.50 | -6.01% | 989.63K | London | |||
| 1,071.50 | 1,115.00 | 1,071.50 | -72.00 | -6.30% | 854.76K | London | |||
| 1,910.00 | 1,944.00 | 1,908.00 | -48.00 | -2.45% | 481.61K | London | |||
| 154.00 | 158.00 | 153.95 | -6.85 | -4.26% | 62.87M | London | |||
| 368.60 | 374.30 | 366.40 | -11.50 | -3.03% | 2.41M | London |